Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Ely

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Blood|March 12, 2005
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferationAchim A Jungbluth, Scott Ely, Maurizio DiLiberto, et al.
Cancer Research|August 4, 2006
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6Linda B Baughn, Maurizio Di Liberto, Kaida Wu, et al.
American Journal of Clinical Pathology|November 20, 2012
Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimensDeepti M Reddi, Chuanyi M Lu, George Fedoriw, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive PatientsScott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Immunity|August 28, 2002
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cellsMichelle R Tourigny, Josie Ursini-Siegel, Hayyoung Lee, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Outcome of deferred initial therapy in mantle-cell lymphomaPeter Martin, Amy Chadburn, Paul Christos, et al.
British Journal of Haematology|August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyRuben Niesvizky, Tara Naib, Paul J Christos, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Blood|March 12, 2005
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferationAchim A Jungbluth, Scott Ely, Maurizio DiLiberto, et al.
Cancer Research|August 4, 2006
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6Linda B Baughn, Maurizio Di Liberto, Kaida Wu, et al.
American Journal of Clinical Pathology|November 20, 2012
Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimensDeepti M Reddi, Chuanyi M Lu, George Fedoriw, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive PatientsScott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Immunity|August 28, 2002
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cellsMichelle R Tourigny, Josie Ursini-Siegel, Hayyoung Lee, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Outcome of deferred initial therapy in mantle-cell lymphomaPeter Martin, Amy Chadburn, Paul Christos, et al.
British Journal of Haematology|August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyRuben Niesvizky, Tara Naib, Paul J Christos, et al.
Pageof 5